[Thrombocyte transfusion: increase in platelets in relation to clinical and immunologic prerequisites]

Area of Science:

• Hematology
• Transfusion Medicine

Context:

• Severe thrombocytopenia presents challenges in managing bleeding risks.
• Platelet transfusions are critical for patients with low platelet counts, including those with hematologic malignancies and bone-marrow transplant recipients.
• Transfusion efficacy is often measured by corrected count increment (CCI).

Purpose:

• To identify factors influencing corrected count increment (CCI) after platelet transfusions in patients with severe thrombocytopenia.
• To evaluate the predictive value of in vitro antibody screenings for transfusion success.

Summary:

• This study analyzed 195 platelet transfusions in 35 patients with severe thrombocytopenia.
• A significant rate of transfusion failure (44%) was observed, defined as CCI < 5 X 10(9) platelets/l.
• Transfusion failures were strongly associated with splenomegaly and fever (54% vs. 29%, p < 0.002).
• In vitro tests, including lymphocytotoxic and radioimmune antiglobulin tests, and HLA antigen identity did not correlate with CCI.
• Antibodies against donor platelets were detected infrequently.
• Clinical condition, particularly fever and splenomegaly, emerged as the most influential factor for post-transfusion platelet increment.

Impact:

• Findings indicate that clinical factors, rather than in vitro antibody screening, are primary determinants of platelet transfusion success in patients with low alloimmunization.
• This underscores the need to consider patient clinical status when assessing transfusion outcomes.
• Highlights limitations of current in vitro methods for predicting transfusion response in this population.